Families of SMA and Repligen Corporation

October 27, 2009

The SMA Foundation congratulates Families of SMA and Repligen Corporation on the announcement of a licensing deal for the development of new compounds for the treatment of SMA. This marks a welcome new stage of advancement in SMA therapeutics development – and a clear demonstration of the value of non-profit drug development activities. For more information, please click here.